Heterozygosity for protein C deficiency is associated with thromboembolic episodes, but clinical symptoms are nonrandomly distributed among protein C deficient families. This finding has led to the provisional definition of clinically dominant and clinically recessive protein C deficiency. We report here the molecular basis of hereditary, clinically dominant protein C deficiency in a panel of 40 Dutch probands from apparently independent families. All but one subject was a heterozygote for a point mutation in the protein C gene. These 39 subjects shared 15 mutations, six of which occurred in more than one proband (between two and nine).
The diversity in the 15 mutations, together with the observation that the most frequent Dutch mutation was also found in a Swedish family with clinically recessive protein C deficiency, makes it unlikely that the molecular basis of protein C deficiency will be different between the clinically dominant and recessive forms. The recurrence of one of the mutations is most likely due to a founder effect, which suggests that when an additional hereditary factor is involved in the clinical severity of protein C deficiency this factor may remain linked to the protein C gene over many generations. 0 1991 by The American Society of Hematology.
These findings contrast sharply with two sets of data that do not support a strong association between heterozygosity for protein C deficiency and thrombotic disease. First, there is the observation that in many instances severely affected homozygous infants were born from heterozygous parents who have neither a personal predisposition to thrombosis nor a family history of Second, the measurement of protein C levels in a large panel of 4,723 healthy blood donors resulted in an estimate of the prevalence of heterozygous protein C deficiency in the general population of 1 in 200 to 300." None of the hereditary protein C-deficient subjects identified in this survey had a personal or family history of thrombosis (clinically recessive protein C deficiency).
These two sets of observations strongly suggest that only in a subset of hereditary protein C deficiencies (one in 50 to 80) is the disorder associated with a predisposition to thrombosis. At present, it is unknown which factor(s) influence the apparently nonrandom distribution of thrombotic symptoms among protein C-deficient families. One possibility is that the genetic abnormality is different between clinically dominant and recessive protein C deficiency. Alternatively, some unidentified additional genetic factor may determine the predisposition towards thrombosis." This factor may cosegregate with protein C deficiency in the symptomatic families, and may have segregated from the protein C defect, at a rate dependent on the genetic distance, in asymptomatic families.
To address these issues one needs to know the primary genetic defect that underlies hereditary protein C deficiency in both symptomatic and asymptomatic families. As a first step, we report here the genetic analysis of a panel of 40 probands of Dutch symptomatic families with clinically dominant protein C deficiency type I. In all but one subject a molecular abnormality due to a point mutation was found. Of the 15 distinct mutations shared by these 39 probrands, six occurred in more than one subject and accounted for 75% of the genetic defects. The recurrence of one of these six mutations was found to be due to "identity by descent" and not to independent mutational events. If an additional genetic factor is involved in the predisposition towards thrombosis, our data suggest that this factor may remain linked to the protein C gene defect over many generations. 
SUBJECTS AND METHODS
All subjects are symptomatic probands from Dutch families with a hereditary protein C deficiency (clinically dominant type). These patients were originally identified by screening patients with a personal and family history of thrombosis. They all have a type I deficiency, ie, a concordant reduction of protein C activity and antigen. The laboratory diagnosis was made using criteria previously described.'* In nine cases, only the DNA of the proband was available for analysis. In the other cases, DNA from normal and deficient family members was available for analysis of the cosegregation of the genetic defect with the deficiency.
The strategy for identifying mutations focussed on finding alterations in the coding sequence of the protein C gene and made use of the polymerase chain reaction (PCR).I3 Primers used in the PCR were derived from the genomic sequence (Table l) ,L4,'5 and were chosen such that each amplified fragment contained the entire coding sequence plus splice junctions of an exon. The conditions used in the PCR were as follows: 0.7 minutes of denaturation at 95"C, 1 minute of annealing at 50"C, and 2 minutes of extension at either 63°C (exons 1,2,3,6,7, and 8), 65°C (exons 4 and 5), or 70°C (exon 9). Further reaction conditions were as described before. 16 After the PCR, the complete reaction mixture was run at 4°C on an ultra-low gelling temperature agarose gel and the segment of the gel containing the amplified fragment was excised. Without further purification, 1 to 5 FL of the gel slice was heated at 95°C for 4 minutes and used as DNA template in a commercially available DNA-sequencing kit (Boehringer Mannheim, Mannheim, Germany) as described before."
For each of the mutations reported here, all nine regions were sequenced to exclude the possibility of more than one sequence abnormality. However, when a particular mutation was found in more than one proband the sequencing of all nine exons was performed only in the first.
RESULTS
Of the 40 protein C-deficient probands in this study, 39 were found to be heterozygous for a point mutation in the protein C gene ( Table 2 ). These 39 subjects shared 15 distinct mutations that varied from splice site and nonsense mutations, which putatively alter normal splicing and translation, to missense mutations of which the relationship to the type I protein C deficiency is not immediately clear. In addition, the proband from family PC44 was not only heterozygous for a '32Gln --* Stop but also for an apparently rare but neutral sequence abnormality in the codon for 17*Arg (CGG + CGA) that did not cosegregate with the protein C deficiency.
Notably, this latter observation raises the possibility that investigators are dealing in part with rare but neutral amino acid sequence variations rather than with mutations that are directly responsible for the protein C deficiency. To minimize this possibility we made certain that the protein C gene sequences that are amplified by the primer sets in Tabe 1 did not contain a second abnormality. In addition, when DNA from normal and deficient family members was available, we compared the inheritance of the protein C deficiency with that of the genetic abnormality. To simplify this analysis, use was made of the finding that 11 of the 15 mutations are readily detectable from an altered digestion pattern for particular restriction enzymes ( Table 2 ). In the remaining cases, the genetic abnormality was monitored by a sequence analysis. For all but three mutations, DNA was available from family members (varying from two to more than 60) for this type of analysis, and invariably cosegregation of protein C deficiencywith the mutation was observed.
Six of the 15 mutations were found in more than one independent proband. Two of these ('"Cys + Tyr and 40311e + Met) occurred two times and one (76Phe + Leu) occurred three times. The remaining three mutations ("'Arg + Cys, I3'Gln + Stop, and "Arg -+ Stop) were considerably more frequent and recurred nine, nine, and five times, respectively. Taken together, these six mutations accounted for 75% (30 of 40) of the mutations.
The recurrent mutations have either arisen indepen- For '4 The total number of family members investigated is in parentheses. Abbreviation: ND, not done because no family members were available for analysis. 'Restriction enzyme that can be used to detect the mutation indirectly. tThe probands have been reported earlier.Ig *This proband also carries a 6247 G + A transition on his normal protein C allele. dently or are "identical by descent" (founder effect). In the case of independent mutational events, their high frequency may be due to hotspots for mutation like the CpG dinucleotides" that are involved in the 230Arg -+ Cys and ' O6Arg -+ Stop mutations. To decide which of the two mechanisms is most likely responsible for the recurrent mutations, one may take geographic and ethnic information into consideration and perform a haplotype analysis of the defective allele. We have previously reported the cosegregation of the M6Arg -+ Stop mutation with a rare intragenic Msp I restriction site polymorphism in three of the five families with the "'Arg -+ Stop mutation." Similarly, the two families that are added in this report carry the %Arg -+ Stop mutation on the rare Msp I allele (data not shown). Because such a linkage between a particular mutation and a rare polymorphism argues against the independent origin of the mutation^'^ we attempted a genealogic investigation of the five families. As shown in Fig 1, by going back to 1757 we found a common ancestor for three of the probands. The remaining two families could not be linked to this pedigree because of a foundling and an unmarried mother in the ancestry.
In addition to the abnormalities in Table 2 and the neutral abnormality in the codon for "'Arg, three apparently neutral and frequent sequence variations were found. The first polymorphism is an A + T transversion at nucleo- tide -1476 (numbering as in Foster et all4) in the untranslated first exon" of the gene with allelic frequencies of 60% (T) and 40% (A) (74 alleles tested). The second polymorphism is a T + G transversion in the triplet coding for 99Ser (TCT -+ TCG, also Ser) with allelic frequencies of 59% (T) and 41% (G) (78 alleles tested). The third polymorphism is a C -+ T transition in the triplet coding for *I4Asp (GAT+GAC) with allelic frequencies of 67% (T) and 33% (C) (78 x alleles tested). This latter polymorphism, which specifies Asp in both sequences, was already predicted by Foster et all4 from a difference between a cDNA and a genomic sequence.
DISCUSSION
The main aim of this study was to establish the genetic basis of clinically dominant protein C deficiency type I in a representative panel of probands from symptomatic families. The results indicate that although there is a considerable heterogeneity in the genetic abnormalities, some of the mutations predominate.
It came as a surprise that 10 of the 15 mutations that are each associated with a type I deficiency predict amino acid replacements. We had expected that a larger proportion of the mutations would lead to stop codons, frameshifts, or splice site abnormalities. Even though we observed a neutral abnormality in the codon for "'Arg, it is unlikely that all of these missense mutations also represent rare but neutral variants of protein C because each was the only mutation observed in the protein C genes of a particular proband, and because invariably cosegregation of a type I protein C deficiency with the genetic defect was observed in the family of the proband. It may be that some of the aminoacid replacements result in the improper folding of the protein C zymogen and that these aberrant molecules are removed from the endoplasmatic reticulum or the Golgi apparatus before secretion through a mechanism that involves so-called "chaperone" proteins.2o"' Alternatively, some of the abnormalities that we classify as a missense mutation may actually be a splite site mutation. For instance, the '19Ser -+ Arg replacement results from a C + G mutation in the sequence. . . AG & TGTGC. . . The newly generated sequence closely resembles the consensus of a donor splice site AG GT AGT," and if actually used would lead not only to an aberrantly spliced RNA but also to a frameshift.
Given the spectrum of mutations in clinically dominant protein C deficiency it is difficult to imagine how these may differ qualitatively from the mutations in clinically recessive protein C deficiency. Many homozygotes born from heterozygous parents without a personal or family history of thrombosis have undetectable levels of protein C. This level of protein C would be compatible with any of the stop codons we found in our panel. Because we have not identified any asymptomatic families in the Dutch population we are not able to test such individuals for the presence of any of the mutations that we report here. We can add, however, that we have identified a 230Arg + Cys mutation (which occurred nine times in our panel) in a Swedish compound heterozygote that was born from parents without a personal or family history of thrombosisz3 (Reitsma et al, unpublished). This finding clearly indicates that, indeed, no qualitative difference in the mutations between symptomatic and asymptomatic families will be found.
The proposal that comparable genetic defects underlie protein C deficiency in symptomatic and asymptomatic families is at odds with the terms clinically dominant and clinically recessive protein C deficiency. These terms suggest that the two forms of deficiency constitute distinct genetic entities. However, until it is established which additional factor(s) determine the susceptibility of a protein C-deficient subject to the development of thrombosis, these terms may remain useful to distinguish the protein C-deficient individuals as they have been claimed to abound in the general population from those that are members of thrombophilic families. These latter individuals, unlike their counterparts in the population at large, carry the protein C deficiency as a dominant marker for increased thrombotic risk.
With respect to the hypothesis that a second abnormality cosegregates with protein C deficiency in the symptomatic individuals,'." the results from the genealogic investigation presented in Fig 1 are intriguing. One way of interpreting these results is that they show that such a hypothetical factor remains linked to the protein C deficiency over many generations and, therefore, should map relatively close to the protein C gene on chromosome 2. The implication of such an interpretation is that the hypothetical factor is not a coagulation protein because all of these have been localized on other chromosomes and any abnormality in these proteins should segregate rapidly from the protein C deficiency. The only exception is the gene for the lipoproteinassociated coagulation inhibitor (LACI) that has recently In the families in which we have identified the genetic abnormality underlying the type I protein C deficiency it will be relatively simple to screen the family for the presence of heterozygotes. At present, the diagnosis relies on assays of protein C antigen and/or activity. However, occasionally this reliance on protein C levels will lead to a misdiagnosis because on the one hand there is an overlap between the plasma levels of normals and heterozygotes and on the other hand there are many patients in which one considers a diagnosis who are taking oral anticoagulants, a treatment that in itself will result in a decrease of the protein C level. By adding a genetic test one can now unequivockbly assign a subject to either the normal or the deficiency group and estimate precisely the correlation between the protein C deficiency and thrombosis. This study is now underway at our institute for the families described in this report.
